WHAT IS THE REVERT PROJECT?

REVERT is a project aiming to address the unmet need arising from an important health challenge: dementia. Most forms of dementia are incurable, and its prevalence increases with age.

Normal pressure hydrocephalus (NPH) is a condition that is often mistaken for dementia. Unlike causes of dementia such as Alzheimer’s disease, the symptoms of NPH can potentially be reversible. The aim of REVERT is to implement innovative medical tools developed by individual partners todiagnose NPH patients quickly and accurately as part of an integrated care pathway.

WHO IS INVOLVED IN THE PROJECT?

REVERT involves cross-border collaboration between hospitals, healthcare academia and industry. It is led by the University of Cambridge in partnership with the University of Picardie Jules Verne and the University of Artois; the university hospitals of Cambridge, Amiens, Brest and Caen; and a healthcare informatics company, Obex Technologies.

Learn more about the project partners here.

HOW IS IT BEING FUNDED?

REVERT was launched in October 2020 and will continue until June 2023. It has a budget of €3.5m of which €2.4m is being funded by the ERDF (European Regional Development Fund) via the Interreg France (Channel) England Programme.


See further information for patients and relatives

See further information for health professionals

EN_GB